Study on Antibacterial Properties of PBT2

Introduction

Researchers from the University of Queensland in Australia have initiated a study to explore the antibacterial properties of PBT2, a drug currently under investigation for treating Alzheimer’s disease. Antibiotic resistance has emerged as a significant global health crisis, with a marked increase in resistant bacteria over the past decade.

Global Impact of Antibiotic Resistance

In the United States alone, more than 2 million infections related to antibiotic resistance occur annually, resulting in approximately 23,000 deaths. In many developing nations, communicable diseases remain the leading cause of mortality, a situation exacerbated by the rise of antibiotic resistance. The problem is intensified by the overuse and misuse of antibiotics, alongside a notable decline in the discovery of new antimicrobial agents. Prominent antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), pose severe challenges in both community and hospital settings.

The Need for Alternative Therapies

Given the escalating issue of bacterial resistance, there is a pressing need for alternative therapies that can complement existing antibiotic treatments.

Overview of PBT2

Drug Development

PBT2 is currently being evaluated as a potential treatment for both Alzheimer’s and Huntington’s diseases. It has successfully advanced to phase 2 clinical trials, where a daily dosage of 250 mg over six months has been deemed safe and well-tolerated by participants.

Mechanism of Action

PBT2 functions as an ionophore, enabling the transport of metal ions, such as zinc, across biological membranes. This action can significantly alter metal homeostasis within cells, leading to increased zinc accumulation in bacterial cells, which may result in bacterial cell toxicity. Furthermore, the combination of PBT2 and zinc has been shown to restore susceptibility to antibiotics in previously resistant bacteria, such as erythromycin-resistant group A Streptococcus (GAS), MRSA, and VRE.

Research Findings

Study Results

The study aimed to assess the therapeutic potential of PBT2 as an antibacterial agent against GAS, MRSA, and VRE. The published results in the journal American Society for Microbiology revealed that neither PBT2 nor zinc exhibited antibacterial activity when used independently. However, their combination demonstrated significant antibacterial effects against all tested bacterial strains. Notably, the bacteria did not develop resistance to this PBT2-zinc combination.

Safety and Efficacy

The safety of PBT2 and zinc in human cells was also evaluated, showing that cell viability remained unaffected by the treatment. Additionally, this combination proved effective in treating murine wound infections by significantly reducing bacterial burden following topical application. The findings suggest that the PBT2-zinc combination has the potential to combat infections by overcoming antibiotic resistance, thereby revitalizing the effectiveness of previously ineffective antibiotics in treating infectious diseases.

Conclusion

The research underscores the promising role of PBT2 in addressing antibiotic resistance, paving the way for new treatment strategies in combating bacterial infections.

Reference

Bohlmann, L., De Oliveira, D.M., El-Deeb, I.M., Brazel, E.B., Harbison-Price, N., Cheryl-Lynn, Y.O., Rivera-Hernandez, T., Ferguson, S.A., Cork, A.J., Phan, M.D., and Soderholm, A.T., 2018. Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance. mBio, 9(6), pp.e02391-18.